ARTV (Artiva Biotherapeutics) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Asset Impairment Charge?

Artiva Biotherapeutics's Asset Impairment Charge for the three months ended in Dec. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Artiva Biotherapeutics Asset Impairment Charge Historical Data

The historical data trend for Artiva Biotherapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Asset Impairment Charge Chart

Artiva Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

4.08

Artiva Biotherapeutics Quarterly Data
	Dec19	Dec20	Mar21	Sep21	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial										-	-	-	-	-

Artiva Biotherapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Artiva Biotherapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Artiva Biotherapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Artiva Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.artivabio.com

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).